Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;9(9):938-939.
doi: 10.1016/S2213-2600(21)00266-6. Epub 2021 Jun 18.

Imatinib in COVID-19: hope and caution

David Bernal-Bello  1 , Alejandro Morales-Ortega  2 , Ana Isabel Farfán-Sedano  3 , Jaime García de Tena  4 , Juan Víctor San Martín-López  3
Affiliations
Comment

Imatinib in COVID-19: hope and caution

David Bernal-Bello et al. Lancet Respir Med. 2021 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DB-B is the principal investigator of a non-sponsored randomised trial investigating the role of imatinib and baricitinib in patients with COVID-19 (NCT04346147); AM-O, AIF-S, JGdT and JVSM-L are co-investigators in this project.

Comment on

  • Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.
    Aman J, Duijvelaar E, Botros L, Kianzad A, Schippers JR, Smeele PJ, Azhang S, Bartelink IH, Bayoumy AA, Bet PM, Boersma W, Bonta PI, Boomars KAT, Bos LDJ, van Bragt JJMH, Braunstahl GJ, Celant LR, Eger KAB, Geelhoed JJM, van Glabbeek YLE, Grotjohan HP, Hagens LA, Happe CM, Hazes BD, Heunks LMA, van den Heuvel M, Hoefsloot W, Hoek RJA, Hoekstra R, Hofstee HMA, Juffermans NP, Kemper EM, Kos R, Kunst PWA, Lammers A, van der Lee I, van der Lee EL, Maitland-van der Zee AH, Mau Asam PFM, Mieras A, Muller M, Neefjes ECW, Nossent EJ, Oswald LMA, Overbeek MJ, Pamplona CC, Paternotte N, Pronk N, de Raaf MA, van Raaij BFM, Reijrink M, Schultz MJ, Serpa Neto A, Slob EMA, Smeenk FWJM, Smit MR, Smits AJ, Stalenhoef JE, Tuinman PR, Vanhove ALEM, Wessels JN, van Wezenbeek JCC, Vonk Noordegraaf A, de Man FS, Bogaard HJ. Aman J, et al. Lancet Respir Med. 2021 Sep;9(9):957-968. doi: 10.1016/S2213-2600(21)00237-X. Epub 2021 Jun 18. Lancet Respir Med. 2021. PMID: 34147142 Free PMC article. Clinical Trial.

References

    1. Morales-Ortega A, Rivas-Prado L, Frutos-Pérez B, et al. Early clinical experience with imatinib in COVID-19: searching for a dual effect. J Infect. 2021;82:186–230. - PMC - PubMed
    1. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016;90:8924–8933. - PMC - PubMed
    1. Han Y, Duan X, Yang L, et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021;589:270–275. - PMC - PubMed
    1. Zhao H, Mendenhall M, Deininger MW. Imatinib is not a potent anti-SARS-CoV-2 drug. Leukemia. 2020;34:3085–3087. - PMC - PubMed
    1. Galimberti S, Petrini M, Baratè C, et al. Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2. Front Oncol. 2020;10 - PMC - PubMed

Substances